Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. [Review]
Citation: Current Oncology Reports. 21(9):84, 2019 08 13.PMID: 31410582Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] | *Lung Neoplasms/dt [Drug Therapy] | *Protein Kinase Inhibitors/tu [Therapeutic Use] | Antineoplastic Agents/pd [Pharmacology] | Antineoplastic Agents/tu [Therapeutic Use] | Carcinoma, Non-Small-Cell Lung/en [Enzymology] | Carcinoma, Non-Small-Cell Lung/ge [Genetics] | Carcinoma, Non-Small-Cell Lung/pa [Pathology] | Clinical Trials as Topic | ErbB Receptors/ai [Antagonists & Inhibitors] | ErbB Receptors/ge [Genetics] | Humans | Lung Neoplasms/en [Enzymology] | Lung Neoplasms/ge [Genetics] | Lung Neoplasms/pa [Pathology] | Molecular Targeted Therapy/mt [Methods] | Mutation | Neoplasm Staging | Protein Kinase Inhibitors/pd [Pharmacology] | Randomized Controlled Trials as TopicYear: 2019ISSN:- 1523-3790
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31410582 | Available | 31410582 |
PURPOSE OF REVIEW: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC.
RECENT FINDINGS: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment.
English